Introduction Portopulmonary hypertension represents a complex cardiopulmonary complication of cirrhosis that significantly impacts prognosis and transplant eligibility. Recent data from the PORTO-DETECT cohort have suggested that even early-stage portopulmonary hypertension, defined using updated hemodynamic criteria, is associated with increased mortality.
Introduction
Portopulmonary hypertension represents a complex cardiopulmonary complication of cirrhosis that significantly impacts prognosis and transplant eligibility. Recent data from the PORTO-DETECT cohort have suggested that even early-stage portopulmonary hypertension, defined using updated hemodynamic criteria, is associated with increased mortality. This has generated considerable interest, particularly regarding whether early disease represents a true biological risk state or simply reflects differences in treatment exposure and detection.
Problem Statement
The key clinical uncertainty is whether early portopulmonary hypertension independently predicts mortality or whether observed outcomes are confounded by treatment bias, patient selection, and methodological limitations inherent to observational studies. Additionally, it remains unclear whether early detection should alter management, given the lack of evidence supporting early therapeutic intervention and the challenges in implementing invasive screening strategies such as right-heart catheterisation.
Summary
The association between early portopulmonary hypertension and increased mortality compared to patients with normal hemodynamics, independent of liver disease severity and portal hypertension. Importantly, no patients were on pulmonary vasodilator therapy at baseline, minimising treatment-related confounding in the early disease group. The authors acknowledge that treatment imbalance and observational design limit causal inference but argue that these factors do not fully explain the observed mortality signal. They emphasise that early portopulmonary hypertension should currently be viewed as a prognostic marker rather than an indication for immediate treatment. The findings support closer surveillance and risk stratification rather than therapeutic escalation. Future prospective studies and dedicated trials are needed to determine whether early intervention can improve outcomes and to define optimal screening strategies in patients with cirrhosis.
Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.